Advertisement

CardioVasc

, Volume 19, Issue 1, pp 44–47 | Cite as

Unterschätzter Faktor in der Hypertoniediagnostik?

Schlechte Adhärenz als Ursache einer pseudotherapieresistenten Hypertonie

  • Markus TölleEmail author
Fortbildung Schwerpunkt Hypertonie

Die wichtigste Ursache der pseudotherapieresistenten arteriellen Hypertonie ist in bis zu 80% der Fälle eine unzureichende medikamentöse Adhärenz der Patienten. Durch z.B. die Bestimmung der Plasma- oder Urinkonzentrationen eingesetzter Antihypertensiva können die Adhärenz bestimmt und so Kosten durch Prävention von Folgeerkrankungen eingespart werden.

Literatur

  1. 1.
    Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–67CrossRefGoogle Scholar
  2. 2.
    Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23CrossRefGoogle Scholar
  3. 3.
    Chow CK, Teo KK, Rangarajan S et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310(9):959–68CrossRefGoogle Scholar
  4. 4.
    Kotseva K, Wood D, De Bacquer D et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23(6):636–48CrossRefGoogle Scholar
  5. 5.
    Robert Koch-Institut, Epidemiologie und Gesundheitsberichterstattung, 2015Google Scholar
  6. 6.
    Falaschetti E, Mindell J, Knott C, Poulter N. Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet. 2014;383(9932):1912–9CrossRefGoogle Scholar
  7. 7.
    Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104CrossRefGoogle Scholar
  8. 8.
    Noubiap JJ, Nansseu JR, Nyaga UF et al. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2018 Aug 7;  https://doi.org/10.1136/heartjnl-2018-313599CrossRefGoogle Scholar
  9. 9.
    Abegaz TM, Shehab A, Gebreyohannes EA et al. Nonadherence to antihypertensive drugs: A systematic review and meta-analysis. Medicine (Baltimore). 2017;96(4):e5641CrossRefGoogle Scholar
  10. 10.
    Pladevall M, Brotons C, Gabriel R et al. Multicenter cluster-randomized trial of a multifactorial intervention to improve antihypertensive medication adherence and blood pressure control among patients at high cardiovascular risk (the COM99 study). Circulation. 2010;122(12):1183–91CrossRefGoogle Scholar
  11. 11.
    Gupta P, Patel P, Štrauch B et al. Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension. 2017;69(6):1113–20CrossRefGoogle Scholar
  12. 12.
    Gupta P, Patel P, Štrauch B et al. Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. Hypertension. 2017;70(5):1042–8CrossRefGoogle Scholar
  13. 13.
    Koçkaya G, Wertheimer A. Can we reduce the cost of illness with more compliant patients? An estimation of the effect of 100% compliance with hypertension treatment. J Pharm Pract. 2011;24(3):345–50CrossRefGoogle Scholar
  14. 14.
    van Schoonhoven AV, van Asselt ADI, Tomaszewski M et al. Cost-Utility of an Objective Biochemical Measure to Improve Adherence to Antihypertensive Treatment. Hypertension. 2018;72(5):1117–24CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Charité — Universitätsmedizin BerlinCampus Benjamin Franklin Med. Klinik mit SP NephrologieBerlinDeutschland

Personalised recommendations